Major Melanoma Treatment Advancement Announced

The New England Journal of Medicine (NEJM) recently published a major report announcing a treatment advancement for the melanoma community, particularly patients with resectable stage III or IV melanoma.

“This practice changing advancement will utilize pembrolizumab both before surgery (neoadjuvant therapy) and after surgery (adjuvant therapy) to increase event-free survival rates,” says MRF board member, deputy director of the Georgetown-Lombardi Comprehensive Cancer Center and report co-author, Michael B. Atkins, MD.  “Additional studies in the neoadjuvant setting will investigate combinations of anti-PD1 with either Ipilumimab, Relatlimab, TIM-3 inhibitors or injectable agents.”

Click here to read the NEJM abstract and full article for more information.